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 2 
Hemostasis occurs at sites of vascular injury where flowing blood forms a clot, a dynamic 31 
and heterogenous fibrin-based biomaterial. Paramount in the clot’s capability to stem 32 
hemorrhage are its changing mechanical properties, the major driver of which are the 33 
contractile forces exerted by platelets against the fibrin scaffold 1 . However, how platelets 34 
transduce microenvironmental cues to mediate contraction and alter clot mechanics is 35 
unknown yet clinically relevant, as overly softened and stiffened clots are associated with 36 
bleeding 2  and thrombotic disorders 3 , respectively. To that end, we developed a high-37 
throughput platelet contraction cytometer to quantify single platelet contraction forces in 38 
different clot microenvironments and found that platelets, via the Rho/ROCK pathway, 39 
synergistically couple mechanical and biochemical inputs to mediate contraction. 40 
Moreover, highly contractile platelet subpopulations present in healthy controls are 41 
conspicuously absent in a subset of patients with undiagnosed bleeding diatheses and 42 
therefore may function as a clinical diagnostic biophysical biomarker.  43 
During clot formation, various physiological cues such as damaged blood vessels or shear forces 44 
initiate platelet activation, adhesion, and the coagulation cascade, which lead to fibrin 45 
polymerization. Activated platelets then aggregate and bind to the nascent fibrin network via the 46 
IIb3 integrin and undergo actomyosin-mediated muscle-like contraction (Extended Data Figure 47 
1, Extended Data Video 1), which significantly decreases the overall clot size while increasing 48 
clot stiffness by several orders of magnitude. While this platelet-driven clot contraction has been 49 
well described in the literature, the mechanistic underpinnings and especially the biochemical 50 
and biophysical parameters that mediate this process remain poorly understood due to 51 
technological barriers. Current assays provide force measurements during clot contraction, 52 
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establishing changes in average platelet force with different diseases 4 , but these operate at the 53 
bulk level 1,3,5,6 . 54 
As recent studies demonstrate, microenvironmental cues such as mechanical properties of the 55 
underlying matrix substrate 7,8 , matrix geometry 9 , biochemical conditions 10 , and shear stress 56 
11,12  all mediate platelet physiology at the single cell level. In addition, clots in the dynamic 57 
hemodynamic environment are innately heterogeneous in which shear rate, fibrin architecture, 58 
and agonist concentration all vary significantly throughout the same clot. Therefore, a high-59 
throughput, single platelet contraction assay is needed to establish and understand the 60 
“fundamental driver” of clot contraction, that is, how an individual platelet integrates 61 
biochemical and biophysical inputs to contract against the microenvironmental fibrin/ogen 62 
network. As fibrin mechanics have been well characterized, 13  deciphering this fundamental 63 
driver of clot contraction is the “missing link” needed to reconstruct higher order clot behavior 64 
and to obtain a comprehensive physical understanding of clot mechanics at multiple length 65 
scales. 66 
To that end, we developed a microfabricated chip that simultaneously measures the contractile 67 
force of hundreds of individual platelets adherent on substrates with varied mechanical 68 
stiffnesses spanning the physiological range, while controlling the biochemical and shear 69 
microenvironment. This system overcomes technical barriers associated with existing techniques 70 
used for single cell analysis, such as the low throughput of atomic force microscopy 8 ; the high 71 
computational needs of traction force microscopy 14 ; or aggregate platelet measurements with 72 
micropillar arrays 15 . Here, an activated platelet adheres to and spans a fibrinogen microdot pair 73 
and contracts the microdot pair together (Figure 1a-c, Extended Data Video 4). As contraction 74 
force is proportional to the fibrinogen microdot area and microdot displacement, relatively high-75 
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throughput measurements conducted with single cell resolution (Figure 1d-e), effectively 76 
creating a “platelet contraction cytometer.” Imaging studies of the fibrin architecture in a 77 
developing clot informed microdot spacing/size (Extended Data Figure 1, Supplementary 78 
Information, and Methods: Optimizing plating), recapitulating the geometry of the in vivo 79 
platelet microenvironment. Since the platelet behavior of spanning and pulling microdots 80 
together is morphologically similar to clot behavior of platelets in fibrin meshes, trends observed 81 
in this system are expected to match those observed in a 3D system. Hydrogel stiffnesses of 5 – 82 
100 kPa were used to approximate the range of mechanical environments encountered by a 83 
platelet within a clot (Extended Data Figure 2). 84 
Because local biochemical agonists, hemodynamics, and mechanical properties of the clot 85 
directly mediate platelet physiology, we further refined our microfluidic system to enable 86 
encapsulation of micropatterned hydrogels of different stiffnesses in adjacent microchannels, 87 
enabling simultaneous testing of substrate stiffnesses, shear conditions, or agonist concentrations 88 
(Figure 2a-b, Extended Data Figure 3). Each measurement of contraction force is not influenced 89 
by confounding effects such as the underlying substrate or neighboring platelet contraction, as 90 
shown by measurements of the gel thickness, stiffness, and microdot independence (Extended 91 
Data Figure 4). As thrombin, a potent physiologic platelet activator, and substrate stiffness both 92 
mediate different signaling pathways 7  that converge in clot contraction 16 , the contraction 93 
cytometer was used to quantify how platelets synergistically integrate both biochemical and 94 
microenvironmental mechanical inputs to modulate contractile forces. Thrombin also converts 95 
fibrinogen to monomeric fibrin, enabling the experiments to more closely resemble the in vivo 96 
clotting environment  17,18 . 97 
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Platelets have a highly nonlinear force curve (Figure 3) with maximum “peak” contraction force 98 
at moderate substrate stiffness and thrombin concentration, both within the physiologic range 99 
found in clots. While the observation of a peak force is similar to myocytes 19 , platelets are 100 
unique in that output force is both mediated and requires a biochemical and mechanical input. 101 
Surprisingly, platelet contraction force is independent of shear stress (Extended Data Figure 5). 102 
As measurements are obtained after initial adhesion in our protocol, this independence suggests 103 
that shear effects are most significant in the early phases of activation. Interestingly, at the 104 
highest tested thrombin concentrations (5U/mL) characteristic of prothrombotic conditions, the 105 
subset of low contractile force platelets increases, thereby lowering the average platelet force 106 
(Figure 3). In addition, at highest stiffness conditions, platelets contract at lower forces 107 
demonstrating that this phenomenon is not simply due to the sensitivity limit of our system 108 
(Extended Data Figure 6).  109 
Mechanistically, we discovered that the substrate stiffness-mediated platelet contractile force is 110 
highly dependent on the Rho/ROCK pathway (Figure 4a). To elucidate the underlying 111 
mechanotransductive mechanisms of how clot stiffness mediates contraction force, we employed 112 
two pharmacologic inhibitors of myosin light chain phosphorylation, ML7 and Y276232, which 113 
inhibit Ca2+/calmodulin-dependent myosin light chain kinase (MLCK) and Rho kinase (ROCK), 114 
respectively. In light of previous results showing that MLCK and not ROCK is essential to 115 
mechanosensitive spreading 7  , our results showing ROCK and not MLCK is essential to 116 
mechanosensitive contraction highlight that the MLCK and ROCK pathways serve 117 
complementary mechanosensing functions in platelets. Previous studies have shown that the 118 
Rho/ROCK pathway is upregulated in cells adhered onto stiff environments 20  (RhoA) and is 119 
associated with stress fiber formation 21  (ROCK). Consistent with this idea is the observation 120 
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that actin polymerization weakly correlates with increasing platelet contractile force (Extended 121 
Data Figure 7). As the platelet is anucleate, our data also demonstrate that mechanosensitive 122 
contraction can occur in the absence of gene expression. 123 
To determine whether these findings on single platelets are related to changes in the bulk 124 
material properties of a blood clot, we conducted ROCK-inhibition experiments using standard 125 
bulk clot contraction assays and bulk clot rheometry. We observed that ROCK-inhibition impairs 126 
bulk clot contraction as compared to the untreated control clots (Figure 4b), whereas MLCK 127 
inhibition did not alter clot contraction (Figure 4c). Bulk clot rheometry experiments, which 128 
enabled simultaneous measurements of storage and loss moduli as well as bulk tensile forces, 129 
revealed that while both control and ROCK-inhibited clots undergo a dramatic stiffening process 130 
during the course of the experiment (Figure 4d), the exerted tensile forces differed but only at 131 
later time points. Specifically, control and ROCK-inhibited clots apply similar forces during the 132 
beginning of clot formation (Figure 4e) when the measured storage and loss moduli are low 133 
(Figure 4d). Over time, as the clots stiffen (Figure 4d), ROCK-inhibited bulk clots begin to exert 134 
lower tensile forces (Figure 4e) and plateau while the control continues to increase over time. 135 
Taken together, these bulk clot contraction observations are consistent with our data on 136 
individual platelet contractile force. In soft environments, both ROCK-inhibited individual 137 
platelet forces and ROCK-inhibited bulk contraction forces are similar to matching controls in 138 
bulk and at the single platelet level. In stiff environments, however, both ROCK-inhibited 139 
individual platelet forces and ROCK-inhibited bulk contraction and forces are substantially 140 
lower than matching controls. As changes in bulk contraction can be due to multiple reasons, 141 
including changes in fibrin or rates of platelet contraction, our ROCK-inhibition single platelet 142 
contraction data coupled with the bulk data, taken together, suggest that platelet contractile force 143 
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alone can mediate these changes in bulk material behavior of clots.  Hence, our data on 144 
individual platelet behavior in varying microenvrionements is not only associated with bulk clot 145 
contraction but can even inform the mechanisms occurring in bulk. Interestingly, the storage and 146 
loss modulus are the same for both ROCK-inhibited and control (Figure 4d), which may be due 147 
to the fact that the storage modulus of a clot is a function of both the density of cross-linking 148 
points 22 , as well as tensioning of loose fibrin fibers 23 .  149 
Since in vitro clot contraction impairment is associated with limiting the maximum force exerted 150 
by a platelet, we hypothesized that low contractile forces measured at the single platelet level are 151 
associated clinical bleeding disorders. To that end, we first measured the platelets from patients 152 
with impaired cytoskeletal machinery, which were expected to have lower contractile forces. 153 
Compared to healthy controls, patients with defective actomyosin machinery such as those with 154 
Wiskott Aldrich (WAS) syndrome, which involve mutations of the actin-related WAS protein 155 
gene, or MYH9-related disorders (MYH9RD), which involve mutations of the non-muscle 156 
myosin IIA gene, lack highly contractile platelets. Blood from WAS and MYH9 patients exhibit 157 
impaired bulk clot retraction, 24,25  but these studies could not definitively pinpoint specific 158 
dysfunction in platelet contraction 25 . In our system, platelets from these patients exhibited 159 
significantly lower contraction force compared to those from healthy individuals in both stiff 160 
(Figure 5a) and soft mechanical environments (Extended Data Figure 8). More specifically, in 161 
these patients, a larger platelet subpopulation exerts near zero contractile force on stiff 162 
environments than for healthy subjects - approximately 30% versus 6% of platelets. Our single 163 
platelet measurements suggest that in these disorders, the impaired clot retraction may be due to 164 
the inability of individual platelets to apply appropriate forces. 165 
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Diminished platelet contractile forces were also found in a subset of a small cohort of patients 166 
presenting with chronic bleeding symptoms but normal clinical hemostasis tests. Specifically, 167 
these individuals have either normal or low-normal laboratory values for complete blood count, 168 
coagulation screening tests, platelet function (via PFA-100 or platelet aggregometry), or von 169 
Willebrand disease panels (Extended Data Table 1, Extended Data Table 2). Interestingly, three 170 
of the five patients showed impaired platelet contractility on stiff gels (Figure 5a), with a notable 171 
platelet subpopulation with forces below 20nN. Our platelet contraction cytometer’s capability to 172 
detect these previous undiagnosable patients with bleeding diatheses, independent of existing 173 
clinical tests of hemostasis, establishes it as a potential new category of diagnostic to evaluate for 174 
platelet dysfunction. 175 
As shown above, a key capability of platelet contraction cytometry is single cell resolution and 176 
the detection of different platelet subpopulations based on contractility, providing a more 177 
nuanced understanding of what influences clot stiffening. Currently used contraction assays 178 
measure only bulk platelet contractility and do not detect the low contractile subpopulation that 179 
potentially correlates with disease. Even amongst our healthy donors, average platelet contractile 180 
forces varied considerably. However, platelet contractility cytometry revealed subpopulations of 181 
highly contractile platelets (with peaks at 30 nN and higher), which is consistent amongst all 182 
healthy donors (Figure 5b). We also observed individuals both with highly variable and highly 183 
consistent platelet contraction at different points in time (Extended Data Figure 9), indicating 184 
that platelet contraction force might be affected by a number of different physiological 185 
conditions, but in aggregate, establish a range that is consistently higher than the subset of 186 
bleeding patients described above. Our test then represents an important step towards the goal of 187 
personalized medicine.  188 
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By precisely controlling the mechanical, chemical, and shear microenvironments, this work 189 
defines the fundamental driver of clot stiffening, thereby providing important, clinically relevant 190 
insights into clot mechanics. The platelet contractility cytometer presented herein entails a 191 
simple fabrication process and represents a key technological advance in rapid, high-throughput, 192 
single cell force analysis. Models linking microscale measurements to macroscale clot mechanics 193 
are now possible, where they were previously hindered by the inherent mechanical complexity of 194 
fibrin and the lack of data on how single platelets sense their microenvironment and apply force. 195 
Our data shows for the first time that trends observed in individually contracting platelets are 196 
mirrored by changes in the bulk material properties of clots. Moreover, single platelet 197 
contraction measurements inform how the material properties of a nascent clot directly affect 198 
platelet contraction and vice-versa, a correlation not accomplished by bulk assays. Our data 199 
further suggests that platelet contraction cytometry has the potential to serve as a useful addition 200 
to existing clinical tests of platelet function, as platelet contraction does not correlate with the 201 
currently used biomarkers of platelet activation (Extended Data Figure 7). Our newfound 202 
understanding of how platelet actuation directly affects clot formation and mechanics can be 203 
used to guide diagnostic strategies for thrombosis and bleeding disorders. Similarly, our 204 
contraction data and findings of the involved mechanotransductive pathways (Rho/ROCK) 205 
inform the development of pharmacological agents aimed at optimizing clot stiffness. Finally, 206 
this reductionist assay could be used to provide insight into other physiologically common cell 207 
and fibrous matrix systems that are often used in tissue engineering 26 .   208 
 209 
  210 
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Methods: 211 
Device design: Fabrication 212 
The device relies on the use of commercially available materials such as thin rolls of PDMS and 213 
rapid fabrication techniques such as laser cutting to achieve fabrication times of less than 8 hours 214 
per batch of devices (Extended Data Figure 3). 215 
Laser cut gel mold 216 
The first layer of the device will hold the polymerized patterned polyacrylamide gels and serve 217 
as the base layer. A laser cutter (Universal Laser Systems, VLS 3.5) is used to pattern long 218 
rectangular holes (1 mm x 25 mm) into a pre-fabricated sheet of PDMS (Rogers HT6240-0.01”) 219 
(Extended Data Figure 3a). The PDMS sheets are ultrasonically cleaned with successive 220 
solutions of diluted Alconox, DI water, and ethanol. The sheets along with 24x40 mm No. 1 221 
coverslips (Fisher Scientific) are then treated with an O2 plasma (Harrick Plasma, PDC-32G) and 222 
covalently bonded together. The bonding is greatly improved after an overnight heat treatment at 223 
60 C. 224 
Once bonded together, the combined PDMS and coverslip piece was silanized. After an O2 225 
plasma treatment, pieces were incubated in a 10% (3-Aminopropyl)trimethoxysilane (Sigma 226 
281778) /90% Ethanol/ 0.01% Glacial acetic acid solution for 90 min at 60C. The pieces were 227 
then vigorously rinsed with 70%ETOH/30% DI water three times, then rinsed with DI water 228 
three times. To improve the PDMS flexibility and surface properties, the pieces were left in DI 229 
water for 1 hour at room temperature. The pieces were then incubated with a 2% glutaraldehyde 230 
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solution at room temperature for 30 minutes, then rinsed with DI water, and dried with 231 
compressed nitrogen. 232 
Ligand (fibrinogen) stamped coverslips and optimal concentration 233 
Stamped coverslips (No 1.5, 18mm x 18mm) were prepared using the lift-off method as 234 
described previously 27  (Extended Data Figure 3b). The silicon mold to create the fibrinogen 235 
microdots was etched using standard lithography and etching techniques to a depth of 800 nm. 236 
Fibrinogen conjugated to AlexaFluor 488, 594, or 647 (Thermo Fisher Scientific) was used 237 
depending on other selected fluorophores in the experiment. The fibrinogen was incubated 238 
on10 mm x 10 mm x 3 mm PDMS squares at 30 g/mL for 1 hour, rinsed off, and dried with 239 
compressed nitrogen. The PDMS squares with incubated fibrinogen were then brought in contact 240 
with O2 treated silicon molds and removed to create a fibrinogen microdot pattern on the PDMS. 241 
The microdot pattern was then transferred onto an O2 plasma treated 18 mm x 18 mm coverslip. 242 
Previous work has demonstrated that platelet spreading is greatly affected by the ligand density 28 243 
. Surprisingly, platelet spreading is enhanced on low ligand density surfaces as compared with 244 
high ligand density surfaces. We attempted to both lower and increase the ligand density on our 245 
gels approximately 10 fold by changing the concentration of fibrinogen incubated on the PDMS 246 
stamps. For cases of low fibrinogen concentration on polyacrylamide gels, platelet adhesion was 247 
greatly diminished on the patterned surface, precluding contraction measurements. In cases of 248 
high fibrinogen concentration, the micropattern shape was often greatly deformed and of 249 
inconsistent brightness upon hydrogel polymerization. As such, our tests focused on 250 
concentrations of 30 g/mL.  251 
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Polyacrylamide gel casting 252 
To create wells for the polyacrylamide gel, the fibrinogen patterned coverslip was inverted and 253 
aligned over the hybrid 25 x 40 mm PDMS glass coverslip. This assembled piece was placed in 254 
an argon filled glovebox (MBraun UNIlab plus) after observing a 30 minute incubation under 255 
vacuum in the glovebox antechamber. In the glovebox, and directly prior to use, pre-mixed 256 
polyacrylamide solutions with appropriate ratios of acrylamide to bis-acrylamide in PBS, were 257 
mixed with N,N,N′,N′-Tetramethylethylenediamine (Sigma Aldrich, T9281), ammonium 258 
persulfate (Sigma Aldrich, A3678), and acrylic acid N-hydroxysuccinimide ester (Sigma, 259 
A8060) 29 . Using a 20 L pipette, gel solutions were cast into the wells and allowed to 260 
polymerize for 90 minutes. Ammonium persulfate concentrations and NHS concentrations were 261 
optimized for an argon atmosphere and are approximately 10x lower than previously published 262 
values 29 . The concentrations used typically create a thin, unpolymerized region near the PDMS 263 
walls, ensuring that the hydrogel is mechanically isolated from the PDMS well. After 264 
polymerization, gels were removed from the glovebox and the 18 mm x 18 mm coverslip was 265 
removed and discarded. Gels were stored in PBS overnight and for up to seven days at 4oC.  266 
Device Characterization 267 
Fabrication of polyacrylamide gel-based systems have previously been shown to be highly 268 
controllable and repeatable 30  and previous experimental research  31  and subsequent mechanical 269 
models 32  determined that for polyacrylamide gels with thicknesses of >70 m, the underlying 270 
glass substrate does not contribute to the locally measured stiffness. Here, the gels within our 271 
microdevice system are consistently >250 m in thickness (Extended Data Figure 4a) ), 272 
effectively preventing substrate effects from the underlying glass surface. We also performed 273 
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atomic force microscopy measurements to determine the stiffness of the gel constructs. 274 
Measurements were performed on polyacrylamide gels in laser cut microchannels using a 275 
colloidal cantilever (sQube, CP-PNPL-PS-A) with a stiffness of 0.08 N/m and 1.98 m diameter 276 
polystyrene sphere. Gel stiffnesses were in agreement with our calculated predicted values, and 277 
those reported by the literature 33  (Extended Data Figure 4b). 278 
Testing was performed to confirm that the microdot pairs are indeed independent of one another 279 
and that a contracting platelet does not affect the mechanics of the neighboring microdot pair. 280 
With this system, the displacement field around the applied point force is expected decay over 281 
relatively short distances, as predicted by previous work  34 . Here, the microdot pairs are spaced 282 
far apart (8 m or greater) relative to the microdot pair displacement caused by platelet 283 
contraction, which is on the order of 1 m or less. At this distance, displacements induced by 284 
neighboring contracting platelets are expected to be negligible. To confirm this, we analyzed the 285 
microdot displacements of a single contracting platelet surrounded by empty microdot pairs in 286 
real time, and show that movement occurs only in the microdots to which the platelet is attached 287 
(Extended Data Figure 4c-d). Some negligible movement may occur below the limit of detection 288 
of 0.05 m, which was determined from measuring peak-to-peak movement in stationary 289 
microdots with no adherent platelets in the vicinity.  290 
PDMS microfluidic top 291 
PDMS microfluidics were cast from a SU-8 (Microchem Inc.) mold to create microfluidic 292 
channels and sized to cover the hydrogel strips. Microfluidics were 22 mm long x 1.5 mm wide, 293 
by 200 m tall. To assemble, the gels were rinsed with DI water and dried to the extent that all 294 
water on the coverslip-PDMS piece was removed. This is greatly facilitated by the fact that the 295 
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PDMS remains hydrophobic and the polyacrylamide gels are hydrophilic. The PDMS 296 
microfluidic was then quickly attached using a laser cut silicone adhesive (3M, 91022) to ensure 297 
that the gels do not dry during assembly. PBS was then flown into the enclosed channels until it 298 
was ready for use. The double sided tape approach is unique in that it provides rapid attachment 299 
of a microfluidic without affecting the patterned proteins. 300 
Coverslip hybrid microfluidic top 301 
The PDMS microfluidics were best suited to experiments requiring the use of shear flow. For 302 
experiments involving static flow conditions, a hybrid lid composed of laser cut PDMS and a 303 
coverslip facilitated imaging. Similar to conditions outlined above, premade PDMS sheets 304 
(Rogers HT6240-0.01”) were laser cut with well patterns, cleaned, and bonded to 18 mm x 305 
18 mm No 1. glass coverslips. Using the same procedure outline in the PDMS microfluidic top, 306 
the coverglass and PDMS hybrid lid is bonded to the hydrogel device layer using laser cut 307 
silicone adhesive. Upon experimental completion, the ends of the device may be sealed with 308 
silicone grease for multi-day storage. 309 
Experimental Methods 310 
Platelet preparation 311 
Healthy blood donors and patient donors had abstained from aspirin in the last two weeks, and 312 
consent was obtained according to GT IRB H15258. Blood was drawn by median venipuncture 313 
into acid-citrate-dextrose (ACD) solution 2. The sample was subsequently centrifuged at 150 G 314 
for 15 min, and the resulting platelet rich plasma was gel filtered into HEPES modified Tyrodes 315 
buffer as described previously 35 . Platelets were diluted to a final concentration of 4 x 106/mL in 316 
Tyrodes buffer to minimize potential paracrine signaling. This equated to an average distance 317 
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between microdot pairs of 30-50 microns depending on the donor. In some experiments, platelets 318 
were incubated for 1 hour with vehicle (dimethyl sulfoxide, DMSO); ROCK inhibitor Y-27632 319 
at 50 m (Sigma Y0503), or MLCK inhibitor at 10 m (Sigma I2764).  320 
For bulk contraction studies, blood was drawn by median antecubital venipuncture into acid-321 
citrate-dextrose (ACD) solution 2. The sample was centrifuged 150 G for 15 min and the 322 
resulting platelet rich plasma was collected, and centrifuged with an additional 10% ACD by 323 
volume at 900G for 5min. The supernatant, platelet poor plasma, was discarded and the platelets 324 
were resuspended into HEPES modified Tyrodes buffer. 325 
Microdevice plating  326 
Immediately prior to loading platelets into the microfluidic the following was added: 5 mM of 327 
CaCl2, 5 mM of MgCl2, 3 g/mL of fibrinogen, thrombin (Haematologic Technologies, Inc), and 328 
any relevant inhibitors. The small dimensions of the microfluifidic ensure that platelets rapidly 329 
move to the ligand interaction region after activation. After 15 minutes, 60 uL of a wash solution 330 
consisting of 5 mM of CaCl2, 5 mM of MgCl2, thrombin, and any relevant inhibitors was used to 331 
remove residual platelets from solution. Thrombin both activates the platelets and converts 332 
microdot fibrinogen into monomeric fibrin, more closely recapitulating the in vivo environment  333 
17,18 . For some experiment involving shear stress, flow was applied using syringe pumps (PhD 334 
Ultra, Harvard Apparatus) with the wash solution to create a shear rates of either 500s-1 or 1000s-335 
1. The adhered platelets were then incubated for 90 minutes, which is several times more than 336 
needed for contraction to ensure that all platelets had sufficient time to reach a final state of 337 
contraction. Platelets were then fixed with a solution of Tyrodes buffer with 4% 338 
paraformaldehyde, 5 mM CaCl2, and 5 mM MgCl2 for 15 minutes.  339 
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Coverslip preparation & plating 340 
In conditions where a platelet sample was extremely rare (WAS, MYH9-RD), was imaged live, 341 
or required later mounting for high resolution imaging, micropatterned gels on 25 mm coverslips 342 
were used. Bottom coverslips were prepared by silanized using the method described above, and 343 
top coverslips were micropatterned using the technique described above. Gels were then 344 
prepared and placed in between the coverslips. Similar plating protocols were used, with the 345 
exception that gel coverslips were placed in 6 well plates, and platelet concentrations were 346 
dropped to 2M/mL. 347 
Plating optimization:  348 
Platelet behavior is affected by many different behaviors paracrine signaling, ligand density 28 , 349 
ligand type, and shear stress 11 . The device presented in this paper sought to quantify changes in 350 
platelet contraction due to differences in substrate stiffness and thrombin concentration, while 351 
holding all other parameters constant. 352 
ADP: Our initial experiments examining the effect of ADP on platelet contraction were 353 
inconsistent for the same individuals and over time. Measured forces were much lower than 354 
thrombin, but were extremely varied in both platelet adhesion and forces.  355 
Platelet Concentration: Platelet behavior may be affected by nearby activated platelets. To 356 
minimize potential confounding effects, the platelet concentration chosen is purposefully low to 357 
ensure an average distance between contracting platelets of approximately 30 to 50 microns. 358 
There may be some enhancement of platelet contraction by neighboring platelets, but early tests 359 
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with and without apyrase found no change in contraction measurements from the presence of 360 
apyrase.  361 
Ligand Density: It is possible that order of magnitude changes in ligand density could affect 362 
outside-in signaling, as shown earlier  7,28 . We sought to examine this phenomenon but were 363 
constrained by the range of ligand densities that can be achieved using this system.  Here, 364 
30 g/mL was optimal, creating well defined, repeatable patterns which supported platelet 365 
adhesion. When the stamping solution was 3 g/mL, platelet adhesion was poor. At 300 g/mL, 366 
the fibrinogen formed sheets which had the propensity to curl, lowering pattern fidelity. Overall, 367 
we expect trends presented here to be preserved on different ligand densities in light of previous 368 
reports 7 showing mechanosensitive trends are similar in low and high ligand density 369 
environments. 370 
Shear Stress: Platelets were incubated for 15 minutes with thrombin concentrations of 0.1 or 371 
1 U/mL on the polyacrylamide gels to ensure adhesion. Shear rates of 500 and 1000 s-1 applied 372 
for 1.5 hours to each thrombin concentration. Platelets were then fixed under flow with 4% PFA 373 
and imaged. No statistically significant differences were observed due to the application of shear 374 
stress from static controls at either thrombin concentration. Activating the platelets and allowing 375 
them to adhere to the fibrinogen under flow would enable shear stress to be applied during the 376 
entire activation process, leading to more firm conclusions that shear does not affect platelet 377 
contraction on fibrinogen with thrombin. Unfortunately, this condition is difficult to test as the 378 
constant flow of platelets also leads to multi-platelet aggregates. 379 
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Immunocytochemistry 380 
After fixation, depending on the experiment, platelets were stained with an appropriate plasma 381 
membrane dye (Cell Mask Deep Red or Cell Mask Orange, Life Technologies). In some 382 
instances, platelets were counterstained with phallodin (Alexa Fluor conjugated, Life 383 
Technologies) or phosphatidylserine with Annexin V (Alexa Fluor conjugated, Life 384 
Technologies). For detecting activated IIb3, FITC-PAC-1 antibody (BD Biosciences) was 385 
applied to platelets after 75 minutes. 386 
Imaging & Mounting 387 
Gels were imaged on a Zeiss LSM 700-405 confocal microscope using a 20x 0.8 NA lens. For 388 
high resolution images, samples were rinsed with DI water, inverted and mounted onto 389 
coverslips (ProLong Gold Antifade, ThermoFisher Scientific). High resolution images of 390 
platelets were obtained using a GE Deltavision OMX Blaze using a 100x, 1.49 NA objective.  391 
For high resolution scanning electron microscopy, samples were extracted from microfluidics, 392 
and incubated overnight in 50% ionic liquid (IL1000, Hitachi) and 50% deionized water. Excess 393 
liquid was wicked away using filter paper. Samples were imaged using a Hitachi SU8230 cold 394 
field emission SEM. 395 
Image Analysis 396 
Images were analyzed using a MATLAB script which measured the fibrinogen microdot areas, 397 
and calculated the center to center distance of the fibrinogen microdots. Due to the high pattern 398 
fidelity, the initial uncontracted distance was taken to be the distance of a neighboring pair of 399 
uncontracted microdots. Although minimized, occasional multi-platelet aggregates identifiable 400 
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by size occurred and were ignored. The current script and data collection is semi-automated, 401 
where confocal images are manually collected, and individual platelet pairs are identified by 402 
hand, then subsequently analyzed by the script. Such a system may readily be adapted for 403 
automation in future studies. 404 
Bulk Isotonic Clot Contraction 405 
Polystyrene fluorimeter cuvettes (Sigma-Aldrich) with attached grids of 1 mm spacing were 406 
incubated with 1% F-127 pluronic (Sigma) at room temperature for 1 hour. A solution consisting 407 
of 2 mg/mL of purified human fibrinogen (FIB 3, Enzyme Research Laboratories), and 250 x 106 408 
washed platelets/mL was prepared. This platelet-fibrin solution was then combined with 1U/mL 409 
of thrombin and 5mM CaCl2 in the cuvette and kept at room temperature. Pictures of clot 410 
contraction were taken every 30 minutes, and clot volume was estimated using the attached grid. 411 
Bulk Isometric Rheometry 412 
Rheological measurements were performed with a stress-controlled rheometer (Anton Paar MCR 413 
502) using cone-plate geometry. The clot was formed in situ and the shear moduli (G’ and G’’) 414 
as well as the normal force were measured as the clot forms. All measurements were done in the 415 
linear regime. Final clots composition consisted of: 2 mg/mL of purified human fibrinogen (FIB 416 
3, Enzyme Research Laboratories), 250 x 106 washed platelets/mL, 1U/mL of thrombin, and 1 417 
mM CaCl2.  418 
 419 
 420 
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 523 
Figure 1: The fundamental unit driving clot stiffening, a single platelet pulling against a 524 
fibrin/ogen substrate, is established by recapitulating the mechanical and biological 525 
microenvironment of the platelet. a, Fluorescently-conjugated fibrinogen microdot pairs are 526 
covalently bound to a deformable polyacrylamide hydrogel of known mechanical properties. As 527 
a platelet adheres and pulls pairs of fibrinogen microdots together, the contractile force is 528 
proportional to the microdot displacement. b, Super-resolution microscopy images of individual 529 
platelets with various degrees of contraction, scale bar is 2 m c, Scanning electron microscopy 530 
image of a platelet contracting a fibrinogen microdot pair, scale bar is 2 m. d, Real time 531 
contractile measurements of 4 single platelets. 532 
 26 
 533 Figure 2: Platelet contraction cytometer - hydrogels with microprinted arrays of fibrinogen 534 
microdots are encapsulated in separate microchannels, enabling the biochemical, mechanical, 535 
and shear microenvironments to be precisely controlled and varied simultaneously. a, A confocal 536 
image showing single platelets (red, contracting against fibrinogen microdot pairs (green) on the 537 
hydrogel surface. Over 20,000 fibrinogen microdot pairs are microprinted on the surface of each 538 
hydrogel encapsulated in each microchannel. b, Each microfluidic device may comprise different 539 
variables,, here four of microchannels comprise of hydrogels of different stiffness. c, A novel yet 540 
relatively simple fabrication process flow enables rapid manufacturing. 541 
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 542 
Figure 3: Biochemical and mechanical cues synergistically mediate platelet contraction force. a, 543 
Maximal platelet contraction occurs at 75kpa substrate stiffness and 1U/mL thrombin. b, Single 544 
platelet force quartiles for physiologically relevant clot stiffnesses and thrombin concentrations. 545 
Platelet contractile forces are highest at a substrate stiffness of 75 kPa or at 5U/mL thrombin. A 546 
minimum occurs at 25 kPa stiffness and 1U/mL thrombin. c, Exploded view of b to aid 547 
visualization. Microenvironmental stiffness has a dominant role over thrombin concentration. 548 
Force attenuation at the highest stiffness conditions suggests a mechanically mediated negative 549 
feedback mechanism governing the upper limits of platelet contraction. n refers to total number 550 
of platelets tested.  551 
 28 
 552 
 29 
Figure 4: Mechanotransductive platelet contraction is mediated by the Rho-associated protein 553 
kinase (ROCK) pathway, as measured with platelet contraction cytometry and standard bulk clot 554 
contraction and bulk clot rheometry. a, The increase in platelet contractile forces with increasing 555 
substrate stiffness is significantly reduced with exposure to Y27623, a pharmacologic ROCK 556 
inhibitor. Pharmacologic inhibition of the myosin light chain kinase (MLCK) with ML7, on the 557 
other hand, did not produce a statistically significant difference in the substrate stiffness-558 
mediated effect on platelet contractile force. Box denotes median and quartiles; whiskers to 1.5 559 
interquartlie range), square denotes median, triangles denotes 1% and 99%. (n = 539, each 560 
condition n>40). * indicates differences from control at same stiffness (p < 0.05 by Mann-561 
Whitney). b, ROCK inhibition impairs bulk clot contraction (n = 4) as compared to the untreated 562 
control clots. c, MLCK inhibition does not change bulk clot contraction (n = 4). d, Oscillatory 563 
rheometry, which enables simultaneous measurements of storage and loss moduli as well as bulk 564 
tensile forces, revealed that both control and ROCK-inhibited clots undergo a dramatic stiffening 565 
process (representative plot from 3 similar experiments shown). The angular frequency and 566 
strain amplitude are 1 rad/s and 0.01, respectively, which are well within the linear regime of the 567 
samples.  e, Control and ROCK-inhibited clots apply similar forces during the beginning of clot 568 
formation when the measured storage and loss moduli are low (n = 3). As the clots stiffen 569 
(Figure 4d), ROCK-inhibited bulk clots begin to exert lower tensile forces and plateau while the 570 
control continues to increase over time. ** indicates difference from control (p < 0.05 by t-test). 571 
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 572 
Figure 5: Patients with phenotypic bleeding lack highly contractile platelets associated with clot 573 
contraction and force generation. a, Wiskott Aldrich Syndrome and May Hegglin Disorder 574 
platelets exhibited significantly reduced contractile forces compared to that of healthy controls 575 
(75 kPa gel stiffness, 1U/mL thrombin). In a subset of patients with bleeding diatheses yet 576 
normal hemostasis tests, platelet contraction was lower than that of normal healthy controls. 577 
b, Histogram data reveal platelet subpopulations of varying contractile forces. Healthy control 578 
platelets comprise high contractility subpopulations, notably absent in platelets from a Wiskott 579 
Aldrich Syndrome patient. In all panels, n refers to number of platelets, Mann-Whitney statistical 580 
test.  581 
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Figure Legends 582 
Figure 1: The fundamental unit driving clot stiffening, a single platelet pulling against a 583 
fibrin/ogen substrate, is established by recapitulating the mechanical and biological 584 
microenvironment of the platelet. a, Fluorescently-conjugated fibrinogen microdot pairs are 585 
covalently bound to a deformable polyacrylamide hydrogel of known mechanical properties. As 586 
a platelet adheres and pulls pairs of fibrinogen microdots together, the contractile force is 587 
proportional to the microdot displacement. b, Super-resolution microscopy images of individual 588 
platelets with various degrees of contraction, scale bar is 2 m c, Scanning electron microscopy 589 
image of a platelet contracting a fibrinogen microdot pair, scale bar is 2 m. d, Real time 590 
contractile measurements of 4 single platelets. 591 
Figure 2: Platelet contraction cytometer - hydrogels with microprinted arrays of fibrinogen 592 
microdots are encapsulated in separate microchannels, enabling the biochemical, mechanical, 593 
and shear microenvironments to be precisely controlled and varied simultaneously. a, A confocal 594 
image showing single platelets (red, contracting against fibrinogen microdot pairs (green) on the 595 
hydrogel surface. Over 20,000 fibrinogen microdot pairs are microprinted on the surface of each 596 
hydrogel encapsulated in each microchannel. b, Each microfluidic device may comprise different 597 
variables,, here four of microchannels comprise of hydrogels of different stiffness. c, A novel yet 598 
relatively simple fabrication process flow enables rapid manufacturing. 599 
Figure 3: Biochemical and mechanical cues synergistically mediate platelet contraction force. a, 600 
Maximal platelet contraction occurs at 75kpa substrate stiffness and 1U/mL thrombin. b, Single 601 
platelet force quartiles for physiologically relevant clot stiffnesses and thrombin concentrations. 602 
Platelet contractile forces are highest at a substrate stiffness of 75 kPa or at 5U/mL thrombin. A 603 
minimum occurs at 25 kPa stiffness and 1U/mL thrombin. c, Exploded view of b to aid 604 
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visualization. Microenvironmental stiffness has a dominant role over thrombin concentration. 605 
Force attenuation at the highest stiffness conditions suggests a mechanically mediated negative 606 
feedback mechanism governing the upper limits of platelet contraction. n refers to total number 607 
of platelets tested. 608 
Figure 4: Mechanotransductive platelet contraction is mediated by the Rho-associated protein 609 
kinase (ROCK) pathway, as measured with platelet contraction cytometry and standard bulk clot 610 
contraction and bulk clot rheometry. a, The increase in platelet contractile forces with increasing 611 
substrate stiffness is significantly reduced with exposure to Y27623, a pharmacologic ROCK 612 
inhibitor. Pharmacologic inhibition of the myosin light chain kinase (MLCK) with ML7, on the 613 
other hand, did not produce a statistically significant difference in the substrate stiffness-614 
mediated effect on platelet contractile force. Box denotes median and quartiles; whiskers to 1.5 615 
interquartlie range), square denotes median, triangles denotes 1% and 99%. (n = 539, each 616 
condition n>40). * indicates differences from control at same stiffness (p < 0.05 by Mann-617 
Whitney). b, ROCK inhibition impairs bulk clot contraction (n = 4) as compared to the untreated 618 
control clots. c, MLCK inhibition does not change bulk clot contraction (n = 4). d, Oscillatory 619 
rheometry, which enables simultaneous measurements of storage and loss moduli as well as bulk 620 
tensile forces, revealed that both control and ROCK-inhibited clots undergo a dramatic stiffening 621 
process (representative plot from 3 similar experiments shown). The angular frequency and 622 
strain amplitude are 1 rad/s and 0.01, respectively, which are well within the linear regime of the 623 
samples.  e, Control and ROCK-inhibited clots apply similar forces during the beginning of clot 624 
formation when the measured storage and loss moduli are low (n = 3). As the clots stiffen 625 
(Figure 4d), ROCK-inhibited bulk clots begin to exert lower tensile forces and plateau while the 626 
control continues to increase over time. ** indicates difference from control (p < 0.05 by t-test). 627 
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Figure 5: Patients with phenotypic bleeding lack highly contractile platelets associated with clot 628 
contraction and force generation. a, Wiskott Aldrich Syndrome and May Hegglin Disorder 629 
platelets exhibited significantly reduced contractile forces compared to that of healthy controls 630 
(75 kPa gel stiffness, 1U/mL thrombin). In a subset of patients with bleeding diatheses yet 631 
normal hemostasis tests, platelet contraction was lower than that of normal healthy controls. 632 
b, Histogram data reveal platelet subpopulations of varying contractile forces. Healthy control 633 
platelets comprise high contractility subpopulations, notably absent in platelets from a Wiskott 634 
Aldrich Syndrome patient. In all panels, n refers to number of platelets, Mann-Whitney statistical 635 
test.  636 
 34 
Extended Data Videos 637 
 \   638 
Extended Data Video 1-3: Platelet contraction in 3d fibrin meshes span and pull adjacent fibers 639 
together of differing stiffness. The fibrin mesh has varying mechanical stiffness due to the 640 
differing thickness and cross linking point density. Here we show three platelets spanning fibrin 641 
filaments and pulling them together over the course of six minutes. White arrows point to same 642 
feature at both time points. Scale bar is 2 m. 643 
  644 
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 645 
Extended Data Video 4: Individual contracting platelet - A single contracting platelet is imaged 646 
during the contraction process. Time elapsed for entire video is 60 minutes.  647 
 36 
Extended Data Figures 648 
 649 
 650 
Extended Data Figure 1: Platelet contraction in 3d fibrin meshes span and pull adjacent fibers 651 
together of differing stiffness. The fibrin mesh has varying mechanical stiffness due to the 652 
differing thickness and cross linking point density. Here we show three platelets spanning fibrin 653 
filaments and pulling them together over the course of six minutes. White arrows point to same 654 
feature at both time points. Scale bar is 2 m.  655 
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 656 
Extended Data Figure 2: Contractile system, mechanical model, and calculated forces as a 657 
function of pinch distance, and limiting cases for stiffness. a-b, The fibrinogen patches are 658 
covalently attached to the underlying hydrogel and move independently. c, Mechanically, this 659 
can be modeled as a platelet pulling on two springs of equivalent stiffness. d, The force a platelet 660 
will exert by pulling the fibrinogen patches together may be calculated from a measurement of 661 
the pinch distance for a range of different hydrogel stiffnesses. When considering force range, it 662 
is important to consider the limiting cases defining mechanical stiffness values e, Platelets 663 
contracting against one another with moving boundaries are expected to have stiffness on the 664 
order of 10 kPa, the value for an activated contracted platelet. f, Platelets contracting in between 665 
fixed boundaries experience isometric contraction. Previous measurements in isometric 666 
contractile conditions found maximal forces of 80nN. g, Platelets pulling a fibrin strand 667 
perpendicular to the principle axis will cause minimal extension of the fibrin, exerting single 668 
nanonewton forces. h, Platelets which extend a single fibrin fiber will need to exert several 10s 669 
of nanonewtons. Neither g nor h consider pre-strain in the fibrin or multiple fibers which will 670 
make the conditions much stiffer.   671 
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 672 
Extended Data Figure 3: Detailed process flow for construction of microfluidic traction force 673 
microscopy test device. Due to the commercial availability of most starting materials, batches of 674 
devices may be made in less than 8 hours.  675 
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 676 
Extended Data Figure 4: Cast polyacrylamide gels in laser cut gaskets are equivalent to macro 677 
systems and enable independent measurements of platelet contractile forces. a, Measurements of 678 
polyacrylamide gels in channels demonstrate that gels are thicker than 70 m to ensure that the 679 
underlying glass substrate does not contribute to the locally measured stiffness (n = 4, error bars 680 
show standard deviation). b, The measured stiffness values are in agreement with estimated 681 
values, and similar to previously published values in the literature. (n = 18 from two different 682 
gels, error bars show standard deviation) c-d, A single contracting platelet on a microdot pair 683 
does not affect the displacement of the surrounding microdot pairs, demonstrating that each 684 
microdot pair is independent from the neighbor. 685 
  686 
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 687 
 688 
 689 
Extended Data Figure 5: Application of shear stress after the initiation of adhesion and 690 
contraction has no statistical change on platelet contractile forces. (a) Shear flow was applied at 691 
100 s-1 with differing stiffness and thrombin concentration (b) Differing shear was applied at 692 
25 kPa and 1 U/mL thrombin. (ncondition ൒ 35, ntotal = 887)  693 
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 694 
Extended Data Figure 6: Platelet microdot displacement and force is reduced as the 695 
environmental stiffness increases. a, Measured microdot displacements become small when the 696 
environmental stiffness is very high at 100 kPa. b, When converted to force, the distances 697 
measured in (a) reveal that a similar range of forces is seen between 75 kPa and 100 kPa stiffness 698 
gels, but that the average force is lower, indicating that on average platelets do not apply high 699 
contraction forces efficiently in very high stiffness environments. Significance by Mann-700 
Whitney,  0.05.  701 
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 703 
Extended Data Figure 7: F-actin intensity weakly correlates with platelet contractile force,  and 704 
no discernable correlation is seen with other markers of platelet activation. a, F-actin content 705 
weakly correlates with contractile force in a variety of different thrombin and mechanical 706 
conditions. Correlation of r > 0.3 at  = 0.05 b, Selected images of a separate experiment with 707 
0.1 U/mL thrombin and 25 kPa of some platelets showing increase and improved organization in 708 
F-actin with increasing contractile force. As indicated in a, there were also some platelets which 709 
did not follow this trend. Little to no correlation in force and c, PAC-1 binding, d, P-selectin 710 
binding, or e, PS exposure was observed.  711 
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 712 
 713 
Extended Data Figure 8: Platelet contractile forces are impaired in individuals with acto-myosin 714 
related cytoskeletal mutations on soft gels. (npatient ൒ 28, ntotal = 598)  715 
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 717 
 718 
 719  720 
Extended Data Figure 9: Platelet contraction for the same donor over time with numbers 721 
indicating time from start. Donor 1 and donor 2 defined the limits of the contraction range 722 
measured for healthy individuals, with donor 1 having a high variability in between 723 
measurements and donor 2 having exceptionally low variability in between measurements. 724 
Donors 3 and 4 were measured at a later time point in the study. (npatient ൒ 30, ntotal = 616) 725 
 726 
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 727 
Study 
ID 
Contractile 
force 
Bleeding history 
Plt 
count 
(103/uL) 
PT (s) 
aPTT 
(s) 
fibrinogen 
(mg/dL) 
Factor 
VIII 
assay 
(%) 
VWF 
Ag (%) 
Ristocetin 
cofactor 
thrombin 
time (s) 
WL05   
easy bruising, spontaneous 
hematomas, hematuria, 
occasional nosebleeds 
210  13.5  30.6  307  137  107  107  16.8 
WL02    heavy menstruation, easy 
bruising and gum bleeding 
229  14  28.9  255  134  96  62  14.9 
WL06  low  frequent prolonged 
nosebleeds, gum bleeding 
245  14.6  29.5  330  127  79  78  16.4 
WL07  low  frequent nosebleeds  348  14.3  29.2  227  163  165  81  19.3 
WL03  very low 
heavy menstruation, easy 
bruising, frequent gum 
bleeding and nosebleeds 
240  13.3  29.9  343  183  60  54  16.4 
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Extended Data Table 1: Patient history and labs for individuals with unknown bleeding disorders 729 
 730 
 731 
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Study 
ID 
Contractile 
force 
Platelet aggregation interpretation by 
hematopathologist 
PFA 
WL05   
normal platelet aggregation and release with 
ADP, arachadonic acid, collagen, ristocetin (low 
and high dose), thrombin 
closure time with collagen/epi ‐ 106 s 
(normal:83‐163 s) and collagen/ADP ‐ 73 s 
(normal:72‐111 s) 
WL02   
normal platelet aggregation and release with 
ADP, arachadonic acid, collagen, ristocetin (low 
and high dose), thrombin 
closure time with collagen/epi ‐ 243 s 
(normal:83‐163 s) and collagen/ADP ‐ 174 s 
(normal:72‐111 s) but Hct at 19.4 
WL06  low 
normal platelet aggregation and release with 
ADP, arachadonic acid, collagen, ristocetin (low 
and high dose), thrombin 
closure time with collagen/epi ‐ 116 s 
(normal:83‐163 s) and collagen/ADP ‐ not 
reported (normal:72‐111 s) 
WL07  low 
Mildly decreased aggregation to low and high 
dose collagen, with normal ATP release. Given all 
other agonists are normal, this finding likely is 
clinically insignificant. Repeat testing may be 
performed if clinically indicated 
closure time with collagen/epi ‐ 107 s 
(normal:83‐163 s) and collagen/ADP ‐ 68 
(normal:72‐111 s) 
WL03  very low 
normal platelet aggregation and release with 
ADP, arachadonic acid, collagen, ristocetin (low 
and high dose), thrombin 
closure time minimally elevated with 
collagen/epi ‐ 177 s (normal:83‐163 s) and 
collagen/ADP ‐ 116 s (normal:72‐111 s) 
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Extended Data Table 2: Interpretation of history and labs for individuals with unknown bleeding disorders by hemopathologist with 734 
PFA data 735 
 736 
Supplementary Information, Myers et al. 
 Supplementary Information 1 
Device design: Mechanics 
Surface traction force microscopy 
By constraining lithographically patterned arrays of fluorescently tagged proteins to a 
polyacrylamide gel surface, the computational and experimental constraints of traditional 
traction force microscopy are greatly reduced 29 . As cells adhere and move protein microdots, 
the independent traction force, T, is calculated as: 
ࢀ ൌ 2ߨܩ࢛ܽ2 െ ߥ 	
where G is the shear modulus, a is the microdot radius,  is Poisson’s ratio, and u is the 
displacement vector. By measuring the displacement of the microdot relative to the starting 
position, the applied force is calculated. Since the shear modulus of polyacrylamide gels may be 
changed by changing the ratios of precursor materials 33 , the mechanical stiffness felt by the 
platelet may be changed independent of other parameters such as the ligand area and density. 
Simplification of traction force microscopy with two microdot system 
Noting that in fibrin clots, platelets may span and pull together two surfaces (Extended Data 
Figure 1), the method above may be simplified even further by spatially separating microdots 
such that platelets preferentially attach to two microdots (Extended Data Figure 2a-b). Here, 
since the gel stiffness is constant, each microdot may be treated as a spring of equivalent 
stiffness, k, displaced from an equilibrium position u1 or u2, as long as the microdot areas are 
approximately equal (Extended Data Figure 2c). By static equilibrium, u1=u2, and the 
displacement of each microdot is: 
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uଵ ൌ uଶ ൌ 12 ሺxୱ െ x୤ሻ	
where xs is the starting distance of the microdots, and xf is the final distance of the microdots. 
The traction force applied by the platelet is the sum of the applied traction forces and may be 
rewritten in terms of starting distance and final distance. 
ܶ ൌ ଵܶ ൅ ଶܶ ൌ 2ߨܩܽ	ݑଵ2 െ ߥ ൅
2ߨܩܽ	ݑଶ
2 െ ߥ ൌ
2ߨܩܽ	
2 െ ߥ ሺݔ௦ െ ݔ௙ሻ	
By rewriting the equations in this form, image post-processing is greatly simplified as only two 
measurements are needed: the final contracted distance and the original uncontracted distance. 
Using this equation, the force as a function of pinch distance may be calculated for a variety of 
different gel stiffnesses (Extended Data Figure 2d). Due to the high precision lithography used 
here, the uncontracted distance may be assumed to be the distance of a neighboring unperturbed 
pair of microdots, and all measurements are performed once the experiment is completed. 
 
Ligand size choice and spacing 
Using a micropatterning 29  approach to traction force microscopy, both ligand area, ligand 
density, and sytem stiffness could be independently controlled and tuned to mimic geometries 
and mechanical stiffnesses experienced in clots. In consideration of the platelet size and mindful 
of lithography and fabrication minimum feature size constraints, we created pairs of fibrinogen 
circular microdots with a radius of 0.8 m, and center to center distance of 4 m (Figure 1). 
These numbers are similar to those seen in previous AFM studies showing that platelets spread 
to an area of approximately 1 m2 when pulling together two fibrinogen coated surfaces 8 , with 
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microdot displacements of approximately 0.5 – 1 m. Such numbers also appeared to be in 
agreement with our own images of platelets contracting in fibrin gels (Extended Data Figure 1, 
Extended Data Video 1). By spacing pairs of microdots least 8 m apart8, platelet contraction 
was effectively confined to a single pair of microdots (Figure 1b) 9 . 
The size of the microdots was an important parameter in confining the platelet interaction to two 
microdots. Platelets are less likely to span to a neighboring microdot when the microdot is large, 
whereas platelets may span many microdots if the microdots are small and closer together. Aside 
from creating an appropriate spatial geometry to interact with platelets, the microdot size is also 
appropriate for optical microscopy. Similarly, based on our force calculations, the microdot size 
is of an appropriate size to confer adequate force sensitivity and resolution. It is important to note 
that since the microdot is also a signaling molecule for platelet contraction via IIb3, that 
changes in the size could affect platelet behavior. However, any changes in platelet behavior due 
to a limited ligand area will be systemic since the ligand area is constant for all experiments. 
Moreover, the data is in agreement with previous atomic force microscopy studies8, which did 
not constrain ligand area.  Also, since the ligand area also matches in vitro clot observations, any 
errors are expected to be minimal. 
After establishing a system of appropriate spatial dimensions, we sought to ensure that the 
stiffness encountered by platelets was similar to those found in clots. At the single platelet level, 
this system is expected to be an analog for either platelet-platelet interactions or platelet-fibrin 
interactions, which are the primary interactions within a clot. A large variety of mechanical 
stiffnesses are encountered within clots, which have bulk elastic moduli between 45 – 70 Pa 36 . 
Activated contracted platelets have stiffness values of ~10 kPa7; whereas individual fibrin fibers 
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have stiffness values of 2 MPa (unligated) or 14.5 MPa (ligated) 37 . Using such values it is 
possible to factor local geometric considerations to estimate the mechanical stiffness and forces 
that platelets are likely to encounter within a clot. Here the goal is to choose an appropriate range 
of PAA gel stiffnesses for use within our system. As such, these estimates will focus on limiting 
cases for the mechanical environment surrounding platelets. This analysis could be carried forth 
from many different perspectives, but here, expected forces on platelets will be calculated and 
compared to values achievable with this system (Extended Data Figure 2c) 
For platelet-platelet interactions, two limiting cases are considered: when contracting platelets 
have free boundaries (Extended Data Figure 2e) and when contracting platelets have fixed 
boundaries (Extended Data Figure 2f). The free boundary case represents the softest interaction 
which could be experienced by platelet-platelet interactions. In the simplified case, platelets are 
free to contract and will apply no force to do so. Practically, the material properties of individual 
platelets will play a dominant role in defining the stiffness of the system. Previous AFM studies 
have determined that activated, contracted platelets have stiffness of 10 kPa 8 . Hence, forces 
associated with such systems are expected to be low on the order of several nN. The fixed 
boundary case represents an interaction in an infinite stiffness environment, where platelets 
experience isometric contraction. Previous studies have already studied such cases and 
determined that contractile forces tend to maximum around 80 nN 8 . Our fibrinogen microdots 
must move in order for contraction to be measured, so PAA gel stiffnesses were chosen which 
would enable platelets to achieve similar forces with less than 1 m of contraction. Here, both 
75 kPa and 100 kPa gel stiffness meet this criteria (Extended Data Figure 2d). 
For platelet-fibrin interactions, the limiting cases are defined by the direction in which a platelet 
pulls on a single fibrin strand, either perpendicular (Extended Data Figure 2g) or parallel 
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(Extended Data Figure 2h). Using atomic force microscopy and fibrin fibers spanned across 
gaps, others have demonstrated that tension built in fibrin networks is through extension of the 
fibrin and not applied moments. Using published values 37  for typical ligated fibrin diameters 
(284 ± 44 nm), lengths (14.7 ± 2.5 m), and modulus (14.5 ± 3.5 MPa), the forces associated 
with these two conditions may be estimated. 
When the platelet pulls perpendicular to the fibrin strand the extension is minimal representing 
the limit of the soft mechanical environment. Here, assuming a 0.5 m platelet contraction, the 
strain, ϵ, is then: 
߳ ൌ Δܮܮ ൌ
√ߜଶ ൅ ܮଶ െ ܮ
20 ൌ 	
√0.5ଶ ൅ 7.35ଶ െ 7.35
7.35 ൌ 0.0023	
 
The associated angle is then: 
ߠ ൌ tanିଵ ൬ 0.57.35൰ ൌ 0.07	
Due to symmetry in this system, and in consideration of static equilibrium, the force applied by 
the fibrin to the platelet is then: 
ܨݏ݅݊ߠ ൌ ܧ	ܣ	߳	ݏ݅݊ߠ ൌ ሺ14.5	ܯܲܽሻ ቀߨ4 ሺ284	݊݉ሻ
ଶቁ ሺ0.0023ሻሺsin 0.07ሻ ൌ 0.15	݊ܰ	
When the platelet pulls the parallel to the fibrin strand, the extension is maximized. Assuming 
that the platelet is capable of pulling 0.5 m, the associated strain is then: 
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߳ ൌ Δܮܮ ൌ
0.5
14.7 ൌ 0.034 
The force is then 
ܨ ൌ ܧ	ܣ	߳ ൌ ሺ14.5	ܯܲܽሻ ቀߨ4 ሺ284	݊݉ሻ
ଶቁ ሺ0.034ሻ ൌ 31	݊ܰ	
Also, if a platelet were pulling on unligated fibers in the developing clot (pre Factor XIII), then 
these values would be an order of magnitude lower. Hence, in examining these limiting cases 
and previously published values for platelet contraction, choosing PAA gels of stiffness between 
5 and 100 kPa (Extended Data Figure 2d) will adequately cover the micromechanical stiffness 
environment that a platelet will experience within a typical clot. 
